Tafamidis meglumine - Pfizer

Drug Profile

Tafamidis meglumine - Pfizer

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Tafamidis free acid; Vyndaqel

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy; Cardiomyopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy
  • Phase III Cardiomyopathies

Most Recent Events

  • 29 Sep 2017 Pfizer initiates a phase-I trial in Healthy volunteers in USA (PO) (NCT03280173)
  • 20 Sep 2017 Pfizer initiates enrolment in a phase I bioequivalence trial in Healthy volunteers in Belgium (PO) (NCT03266705)
  • 14 Sep 2017 Pfizer plans a phase I trial in Healthy volunteers in Belgium (NCT03280173)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top